PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
2.25
Current Ratio 0.75–0.9x Drug Manufacturers - Specialty & Generic median of 2.59. John Neff would want to see better short-term coverage or stable cash flows.
1.51
Quick Ratio 0.75–0.9x Drug Manufacturers - Specialty & Generic median of 1.95. John Neff might push for better working capital control.
1.05
Cash Ratio 1.25–1.5x Drug Manufacturers - Specialty & Generic median of 0.96. Mohnish Pabrai might see the market undervaluing high immediate liquidity.
-5.50
Negative interest coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize earnings quality and look for debt restructuring catalysts.
-0.43
Negative short-term coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize cash flow quality and look for immediate refinancing solutions.